Gemzar健擇

Gemzar

gemcitabine

Manufacturer:

Eli Lilly

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Gemcitabine HCl
Indications/Uses
Locally advanced or metastatic bladder cancer in combination w/ cisplatin, locally advanced or metastatic pancreatic adenocarcinoma. Locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination w/ cisplatin. Locally advanced or metastatic epithelial ovarian carcinoma who have relapsed following recurrence-free interval of at least 6 mth after platinum-based 1st line therapy, in combination w/ carboplatin. Unresectable, locally recurrent metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy in combination w/ paclitaxel.
Dosage/Direction for Use
NSCLC 1,000 mg/m2 by 30-min IV infusion once wkly for 3 wk followed by 1 wk rest. The 4-wk cycle is then repeated. Combination w/ cisplatin: 1,250 mg/m2 as 30-min IV infusion on day 1 & 8 of each 21-day cycle. Cisplatin at doses between 75-100 mg/m2 once every 3 wk. Pancreatic adenocarcinoma 1,000 mg/m2 by 30-min IV infusion once wkly for up to 7 wk followed by 1 wk rest. Subsequent cycles: Once wkly for 3 consecutive wk out of every 4 wk. Bladder cancer 1,000 mg/m2 by 30-min IV infusion on days 1, 8 & 15 of each 28-day cycle, in combination w/ cisplatin 70 mg/m2 on day 1 or day 2 of each 28-day cycle. The 4-wk cycle is then repeated. Breast cancer Paclitaxel 175 mg/m2 as 3-hr IV infusion on day 1, followed by gemcitabine 1,250 mg/m2 by 30-min IV infusion on days 1 & 8 of each 21-day cycle. Ovarian cancer 1,000 mg/m2 by 30-min IV infusion on days 1 (in combination w/ carboplatin on day 1 w/ a target AUC of 4 mg/mL·min) & 8 of each 21-day cycle.
Contraindications
Special Precautions
Monitor platelet, leukocyte & granulocyte counts prior each dose. Impaired bone marrow function, renal or hepatic impairment. Concomitant w/ radiotherapy. Yellow fever & live attenuated vaccines, CV events, controlled Na diet. Discontinue if capillary leak & pulmonary effects occur during therapy. May impair ability to drive or operate machinery. Prolonged infusion & increased dosing frequency may increase toxicity. Male infertility. Pregnancy. Childn <18 yr.
Adverse Reactions
Leucopenia, thrombocytopaenia, anaemia, dyspnoea, nausea, vomiting, alkaline phosphatase, ALT & AST elevations, allergic skin rash, alopecia, haematuria, mild proteinuria, flu-like symptoms, oedema/peripheral oedema.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01BC05 - gemcitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Gemzar powd for soln for infusion 1 g
Packing/Price
1's
Form
Gemzar powd for soln for infusion 200 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in